There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on AstraZeneca (AZN – Research Report) and Aprea Therapeutics (APRE – Research Report) with bullish sentiments.
AstraZeneca (AZN)
In a report released today, Steve Scala from TD Cowen maintained a Buy rating on AstraZeneca. The company’s shares closed last Wednesday at $76.97, close to its 52-week high of $77.94.
According to TipRanks.com, Scala is a 4-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for AstraZeneca with a $80.75 average price target, which is a 5.0% upside from current levels. In a report issued on May 3, Berenberg Bank also maintained a Buy rating on the stock with a $81.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Aprea Therapeutics (APRE)
Maxim Group analyst Jason McCarthy maintained a Buy rating on Aprea Therapeutics yesterday and set a price target of $16.00. The company’s shares closed last Wednesday at $5.80.
According to TipRanks.com, McCarthy is ranked 0 out of 5 stars with an average return of
Aprea Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $15.67, a 167.0% upside from current levels. In a report issued on May 14, H.C. Wainwright also reiterated a Buy rating on the stock with a $20.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on AZN:
- AstraZeneca CEO Granted Performance Shares
- AstraZeneca withdraws Covid vaccine worldwide, Independent says
- UK Stocks: AstraZeneca (AZN) to Withdraw COVID Vaccine as Demand Wanes
- AstraZeneca price target raised to 13,000 GBp from 12,000 GBp at Berenberg
- AstraZeneca Advances in Gene Therapy with Cellectis Stake
